

The physical association of the P2Y<sub>12</sub> receptor with PAR4 regulates arrestin-mediated Akt activation

Aasma Khan, Dongjun Li, Salam Ibrahim, Emer Smyth, and Donna S. Woulfe

Department of Biological Sciences, University of Delaware, Newark, DE, USA. (A.K., D.L., D.W.)

Institute for Translational Medicine and Pharmacology, University of Pennsylvania, Philadelphia, PA, USA. (S.I., E.S.)

Running Title: P2Y12 dimerizes with PAR4 to co-regulate arrestin signaling

Corresponding author: Donna Woulfe, PhD

Department of Biological Sciences, University of Delaware, Room 349 Wolf Hall,  
105 The Green, Newark, DE 19716. Tel.: 302-831-0850, Fax: 302-831-2281; E-mail:  
[dswoulfe@udel.edu](mailto:dswoulfe@udel.edu)

Text: 39 pages

Tables: 0

Figures: 8

Supplemental Figures: 2

References: 46

Abstract: 250 words

Introduction: 747 words

Discussion: 1489 words

Abbreviations:

BRET, Bioluminescence Resonance Energy Transfer; PAR4, Protease activated receptor 4; GPCR, G protein coupled receptor, TM, Transmembrane helix, TP receptor, Thromboxane A2 receptor.

**Abstract:**

It is now well-accepted that PAR1 and PAR4 have differential roles in platelet activation. PAR4, a low affinity thrombin receptor in human platelets, participates in sustained platelet activation in a P2Y12-dependent manner; however, the mechanisms are not defined. Our previous studies demonstrated that thrombin induces the association of PAR4 with P2Y12, together with arrestin recruitment to the complex. Here we show that PAR4 and P2Y12 directly interact to co-regulate Akt signaling following PAR4 activation. We observed direct and specific interaction of P2Y12 with PAR4, but not PAR1 by Bioluminescent Resonance Energy Transfer (BRET) when the receptors were co-expressed in HEK293T cells. PAR4-P2Y12 dimerization was promoted by PAR4-AP and inhibited by P2Y12 antagonist. Using sequence comparison of the transmembrane domains of PAR1 and PAR4, we designed a mutant form of PAR4, 'PAR4SFT', by replacing LGL194-196 at the base of transmembrane domain 4 with the corresponding aligned PAR1 residues SFT 220-222. PAR4SFT supported only 8.74% of PAR4-P2Y12 interaction, abolishing P2Y12-dependent arrestin recruitment to PAR4 and Akt activation. Nonetheless, PAR4SFT still supported homodimerization with PAR4. PAR4SFT failed to induce a calcium flux when expressed independently; however, co-expression of increasing concentrations of PAR4SFT together with PAR4 potentiated PAR4-mediated calcium flux, suggesting that PAR4 act as homodimers to signal to Gq-coupled calcium responses. In conclusion, PAR4 LGL (194-196) governs agonist-dependent association of PAR4 with P2Y12 and contributes to Gq-coupled calcium responses. PAR4-P2Y12 association supports arrestin-mediated sustained signaling to

Akt. Hence, PAR4-P2Y<sub>12</sub> dimerization is likely to be important for the PAR4-P2Y<sub>12</sub> dependent stabilization of platelet thrombi.

## Introduction:

Platelets are key players in hemostatic plug formation at sites of vascular injury, but can also precipitate thrombotic events under conditions such as atherosclerotic plaque rupture. Platelet accumulation is initiated at a site of injury by contact with extracellular matrix proteins, then extends due to activation by soluble agonists. All soluble platelet agonists bind to G protein-coupled receptors (GPCRs). Thrombin, the most potent platelet agonist, is a serine protease and cleaves the N-terminal exodomains of two human platelet GPCRs: PAR1 and PAR4 (Protease activated Receptors), exposing tethered ligands which activate the receptors. Activated platelets also release ADP, which binds to two GPCRs on platelets: P2Y<sub>12</sub> and P2Y<sub>1</sub>. P2Y<sub>12</sub> is the target of clinically-effective antithrombotic drugs such as Clopidogrel and Prasugrel and functions by inhibiting cAMP levels and activating PI3K pathways to extend and stabilize platelet plug formation (Foster et al., 2001; Niitsu et al., 2005; Savi et al., 2006).

Research in the last decade has increased our understanding of the regulatory control elicited by the dual thrombin receptor system of human platelets (PAR1 and PAR4). PAR1 requires lower amounts of thrombin for activation than PAR4 (Covic et al., 2000) and lowers the amount of thrombin required for PAR4 activation (Leger et al., 2006). The signaling events elicited by each receptor also reflect their differential roles in the thrombus: for example, PAR1 induces an acute and short-lived rise in cytosolic calcium and  $\alpha_{IIb}\beta_3$  activation, whereas PAR4 causes a steady and sustained rise in calcium and  $\alpha_{IIb}\beta_3$  activation which largely depends on P2Y<sub>12</sub> (Holinstat et al., 2006; Shapiro et

al., 2000; Tadokoro et al., 2011). There is a major difference in the mechanisms of cellular trafficking and recycling of PAR1 and PAR4, wherein activated PAR1 gets phosphorylated at serine residues in its cytoplasmic tail and is rapidly internalized independent of arrestins (Hoxie et al., 1993; Trejo and Coughlin, 1999); in contrast, PAR4 is not phosphorylated and internalized rather slowly (Kahn et al., 1999; Shapiro et al., 2000). We have previously shown that inhibition of P2Y12 reduces PAR4-mediated Akt activation and recruitment of arrestin-2 to PAR4 signaling complexes. We further showed that PAR4 and P2Y12 co-immunoprecipitate upon PAR4 activation in human platelets (Li et al., 2008; Li et al., 2011). In this report, we investigate the possibility that direct association of P2Y12 and PAR4 mediates arrestin recruitment to PAR4 and contributes to the consequent Akt activation.

Dimer- or oligomerization of GPCRs has increasingly been reported in platelets (de la Fuente et al., 2012; Frey et al., 2013; Leger et al., 2006; Savi et al., 2006) and other cell types (Angers et al., 2002; Rozenfeld and Devi, 2011). Structure/function studies of GPCR oligomerization have demonstrated that the transmembrane helices (TM), most commonly TM4-6 of GPCRs, provide the interfaces for dimerization of many GPCRs (Filizola and Weinstein, 2005). Homo- or heterotypic interaction of GPCRs affects their pharmacological properties, interactions with scaffolding molecules, and downstream signaling events. For example, it has previously been shown that paired activation of both components of M3 receptor dimers is required for beta-arrestin recruitment to the receptor ((Novi et al., 2005). More recently, PAR1-PAR2 heterodimers were shown to elicit arrestin-dependent signaling to endosomes (Lin and Trejo, 2013). With these models in mind, we expressed fluorescent and luciferase-tagged forms of PAR4 and

P2Y<sub>12</sub> in a heterologous expression system to determine whether the receptors directly interact using Bioluminescent Resonance Energy Transfer (BRET) and to determine whether signaling responses in the cells were dependent upon their direct interaction. We demonstrate that PAR4 and P2Y<sub>12</sub> specifically and directly interact, whereas PAR1 and P2Y<sub>12</sub> do not. PAR1 and PAR4 show specific sequence divergence at the base of TM4. Interestingly, TM4 of PAR4 has been reported to be necessary for its homodimerization (de la Fuente et al., 2012) and could potentially regulate heterodimer formation with other receptors. Hence, using a site-directed mutagenic approach, we designed a mutant variant of PAR4 (PAR4SFT) containing a 3-amino acid substitution at the base of TM4 (based upon PAR1 sequence at this location). We show that PAR4SFT does not interact with P2Y<sub>12</sub> and fails to support P2Y<sub>12</sub>-dependent arrestin recruitment and Akt activation. Interestingly, PAR4SFT also fails to support Gq-mediated calcium mobilization when expressed on its own, but this response could be rescued by its dimerization with (wildtype) PAR4. We conclude that the agonist-dependent specific interaction of PAR4 with P2Y<sub>12</sub> supports sustained signaling to Akt that is partially dependent on recruitment of arrestin-2 to PAR4, and this mechanism is likely important for the PAR4 and P2Y<sub>12</sub>-dependent stabilization of platelet thrombi.



## Materials and Methods:

**Materials:** Unless otherwise specified, reagents were from Sigma-Aldrich (St. Louis, MI, USA). ADP and human thrombin was from Chronolog Corp (Havertown, PA, USA). AYPGKF was from Biopeptek (Malvern, PA). Antibodies were from Cell Signaling (Boston, MA) (anti-Akt, Phospho-Akt-ser473, Pan-actin, Alexa-488 conjugated anti Rabbit and anti Mouse), Santa Cruz (Santa Cruz, CA) (for anti-arrestin-2, PAR4 and P2Y12), Abcam, (Cambridge MA) (anti Flag), MBL (Woburn MA) (anti GFP). Other reagents were from Invitrogen (Grand Island, NY) (BAPTA-AM, Fluo4AM and Pluronic Acid F-127).

## Methods

Plasmid constructs and cell culture: Rluc-PAR4 and Rluc-P2Y12 were generated by subcloning cDNAs for human PAR4 and human P2Y12 into the codon-humanized Renilla luciferase vectors pRLuc N1 (gift from Emer Smyth, University of Pennsylvania, Philadelphia, PA). Enhanced yellow fluorescent protein (EYFP)-PAR4 (PAR4-EYFP), PAR4SFT-EYFP, PAR1-EYFP and P2Y12-EYFP were generated by cloning cDNA for PAR4, PAR4SFT, PAR1 and P2Y12 into the expression vectors pEYFP N1 (gift from Emer Smyth, University of Pennsylvania, Philadelphia, PA). The HA or Flag tagged human PAR4, PAR4SFT, PAR1 and P2Y12 constructs were obtained by subcloning human PAR1, PAR4, PAR4SFT and P2Y12 into HA pcDNA 3.0 or Flag pcDNA 3.0 vector (gift from Ji-Fang Zhang, Thomas Jefferson university, Philadelphia, PA). V5-PAR4-GFP was a gift from Dr. Marvin Nieman (Case Western Reserve University, Cleveland, OH). HA-PARSFT-GFP was constructed by subcloning HA-PARSFT into

codon- humanized pGFP2-N2 vector (gift from Marvin Nieman, Case Western Reserve University, Cleveland, OH)

Human embryonic kidney (HEK)293T cells were maintained in DMEM containing 10% fetal calf serum and 1% penicillin/streptomycin at 37°C and 5% CO<sub>2</sub>. Cells were transfected with Fugene6 or TransIT293 transfection reagent (Mirus Bio LLC).

Generation of Stable cell Lines: HEK293T cells were co-transfected with Flag tagged P2Y<sub>12</sub> pcDNA 3.0 and HA tagged PAR4 or HA tagged PAR4SFT pcDNA 3.0 construct using Fugene6 (Promega, Madison, WI) and selected using 400µg/ml of Hygromycin (for P2Y<sub>12</sub>) and 1000µg/ml of Neomycin (for PAR4 and PAR4SFT) for 2 weeks. Stable cells were maintained in 200µg/ml of Hygromycin and 500µg/ml of Neomycin.

Bioluminescence resonance energy transfer (BRET) assay: HEK293T cells were grown in 6 cm dishes and transiently transfected with Rluc donor plasmid (0.18-0.36µg/dish) and EYFP-acceptor (varying from 0.18-7.2 µg/dish to achieve the required ratio of acceptor:donor from 1:1 to 20:1) and balanced with an empty pcDNA3 vector to maintain equal amount of DNA transfected per dish (7.2µg) using FuGENE 6 transfection reagent (Promega). For optimization of BRET conditions, the acceptor-donor ratio was varied. The optimum ratio of 1:1 to 20:1 of co-transfection was used for the subsequent transfections. Cells were detached using HBSS-EDTA 48 hrs after transfection, washed and resuspended in PBS containing 0.1% glucose and 1mM Ca<sup>++</sup> and Mg<sup>++</sup>, then transferred into 96-well black optiplates (PerkinElmer) (1X 10<sup>5</sup> cells/well/50ul) to assess EYFP expression by measuring EYFP emission using fluometry (Excitation at 485nm

and Emission at 535nm) on a Victor 3 multilabel plate reader (Perkin Elmer) without the addition of coelenterazine h. Fold over basal (FOB) YFP emission was plotted against Ratio YFP:Rluc of amount of constructs used to co-transfect per dish, to check for increase in YFP expression from ratio 1:1 to 20:1 (see supplement figure 1). For BRET 48 hrs after transfection cells were collected post treatment with agonist or antagonist then transferred to 96-well white plates (PerkinElmer). Coelenterazine H (Invitrogen) was added in PBS to a final concentration of 5 $\mu$ M, and donor (475nm) and acceptor (535nm) readings were collected immediately using Victor3 (Perkin Elmer) that allows simultaneous dual emission detection. Cells were kept at 37°C throughout the BRET measurements. The BRET ratio was calculated as (535nm emission/475nm in test cells)-(535nm emission/475nm in control cells transfected with Rluc donor alone) and multiplied by 1000 to calculate the milli Bret units (mBU). The milli BRET units were plotted as a function of YFPFOB values to assess saturable interaction between the donor and acceptor (data not shown for each assay, see supplement figure 1). The mBU values were then expressed as a percent of the maximal Bret reached (maximal mBU) and plotted as a function of ratio of YFP:Rluc of amount of constructs used for co-transfections per dish (1:1 to 20:1).

Immunoblotting: HEK293T cells stably expressing PAR4 and P2Y12 (2 x 10<sup>6</sup> cells/ml) were grown to 70% confluency, and starved for 12 hours. They were then treated with agonist for 10 minutes at 37°C or antagonist for 10 minutes at room temperature; lysed in 1X lysis buffer (1% triton-100, 150 mM NaCl, 10 mM Tris, 0.5% deoxycholic acid, 5 mM EDTA, 0.5 mM PMSF, pH 7.4) with freshly added 1% Triton, 1X protease inhibitor

and 1X phosphatase inhibitor (Sigma-Aldrich). Lysates were resolved on 10% SDS-PAGE and immunoblotted with an antibody to Akt phospho-ser 473 or Pan-actin (Cell Signaling Technology, Beverly, Ma, USA), PAR4 or P2Y12 (Santa Cruz, Santa Cruz CA) at a 1:1000 dilution, then anti-rabbit or anti-Goat HRP and exposed on a film.

Immunoprecipitation (IP): Samples ( $8 \times 10^8$  platelets/ml or  $8-10 \times 10^6$  HEK293T cells/ml) were treated with antagonist (MeSAMP) for 10 minutes at room temperature or  $20\mu\text{M}$  BAPTA-AM for 10min at  $37^\circ\text{C}$ . Agonist was added in a  $5\mu\text{l}$  volume to  $500\mu\text{l}$  platelets per sample and incubated for 10 minutes at  $37^\circ\text{C}$ ; platelets were lysed by addition of 2xIP buffer (1% NP40, 150mM NaCl, 10mM Tris, 1mM  $\text{Na}_3\text{VO}_4$ , 5 mM EDTA, 0.5mM PMSF, pH 7.4) containing a cocktail of protease inhibitors (Sigma-Aldrich). HEK 293T cells were lysed by addition of 1xIP buffer (1% triton-100, 150mM NaCl, 10mM Tris, 0.5% deoxycholic acid, 5mM EDTA, 0.5mM PMSF, pH 7.4) containing a cocktail of protease inhibitors (Sigma-Aldrich). Lysates were rotated at  $4^\circ\text{C}$  for 30 minutes and spun 30 minutes at 12,000xg. Antibodies or control IgG were added to lysates ( $2\mu\text{g}$ /per sample) and rotated at  $4^\circ\text{C}$  overnight followed by proteinA/G agarose  $15\mu\text{l}/\text{ml}$  at  $4^\circ\text{C}$  for 2 hours. Samples were washed with 1x IP buffer 3 times and applied in Laemmli buffer to 10% SDS-PAGE for immunoblotting.

Calcium mobilization assay: HEK293T cells were transiently transfected and/or co-transfected with V5-PAR4-GFP and HA-PAR4SFT-GFP. Co-transfections were done as PAR4:PAR4SFT in increasing ratios 1:1 and 1:2, where  $0.1\mu\text{g}$  of PAR4 was used since it gave the smallest detectable calcium flux. 48hr post-transfection cells were removed

from plates with Versene, washed and resuspended in tyrodes buffer. Cells ( $2.0 \times 10^5$  cells /sample) were loaded with  $10 \mu\text{M}$  Fluo4AM (Invitrogen) in Tyrode's buffer (137 mM NaCl, 5.6mM glucose, 1 g/l BSA, 1mM  $\text{MgCl}_2$ , 2.7mM KCl, 3.3mM  $\text{NaH}_2\text{PO}_4$ ) in presence of Pluronic acid F-127 (Invitrogen) 0.01% for 20 min at  $37^\circ\text{C}$ . This was diluted 1:1 with tyrodes buffer containing 1mM calcium. Basal levels of cytosolic calcium were recorded on AccuriC6 flowcytometer (BD Biosciences) for 1min and then PAR4-AP: AYPGKF (2mM) was added; without interrupting the real time calcium flux measurement; to record the response for 10 min. The data were analysed using FCS express Ruo version 4 where the fluo4 intensity changes over time were converted into % Above threshold by gating the calcium levels pre and post agonist treatment.

Flow cytometry to assess surface expression of receptors: HEK293T cells stably/transiently expressing Flag-P2Y12 or HA-PAR4 or HA-PAR4SFT were collected in Versene and washed and resuspended in DMEM+10%FBS.  $1 \times 10^6$  cells per sample were incubated in anti Flag (1:100), or anti HA (1:50) for 1hour on ice with intermittent mixing. Cells were washed with DMEM+ 5% FBS twice, then incubated with Alexa-488 tagged rabbit or mouse secondary antibodies (Cell Signaling), to detect Flag and HA tag respectively, for 1 hour on ice with intermittent mixing. Cells were then washed twice with DMEM+ 5% FBS, fixed with 2% paraformaldehyde for 10minutes at room temperature and read on FACS caliber (BD Biosciences).

Platelet isolation and preparation of Human blood: Blood for biochemical studies of human platelets was collected by venipuncture from adult human volunteers after

providing written informed consent as approved by the Institutional Review Board at University of Delaware. Blood was collected into a 60-cc syringe containing ACD (trisodium citrate, 65mM; citric acid, 70mM; dextrose, 100mM; pH 4.4) at a ratio of 1:6 parts ACD/blood. Anticoagulated blood was spun by centrifugation at 250xg and the supernatant containing platelet rich plasma (PRP) was then pelleted at 750xg (10 minutes), washed once in HEN buffer (10mM HEPES, pH 6.5, 1mM EDTA, 150mM NaCl) containing 0.05 U/ml apyrase and platelets resuspended with HEPES-Tyrode's buffer (137mM NaCl, 20mM HEPES, 5.6mM glucose, 1 g/l BSA, 1mM MgCl<sub>2</sub>, 2.7mM KCl, 3.3mM NaH<sub>2</sub>PO<sub>4</sub>) at a concentration of from 4x10<sup>8</sup> platelets/ml in HEPES-Tyrode's buffer containing 0.05 U/ml apyrase, for immunoblotting, immunoprecipitation.

Statistical analyses: Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA). For pairwise comparisons, unpaired t-tests were performed. For comparisons across three groups or larger one-way ANOVA, followed by post hoc tests (Tukey Kramer) were performed. p values= \* <0.05, \*\* <0.01, \*\*\*<0.001, were considered significant. Data are shown as means ± S.E.M.

## **Results**

### PAR4 directly associates with P2Y12 upon receptor activation:

We have previously shown that PAR4 and P2Y12 co-immunoprecipitate upon thrombin stimulation of human platelets and that this interaction, as well as PAR4 recruitment of arrestin-2 and signaling to Akt, is prevented in the presence of P2Y12 antagonists (Li et al., 2011). To determine whether physical association of the two receptors may contribute to their signaling responses, we first determined whether physical association of the two receptors is detected in a heterologous expression system. HEK293T cells were transfected with Rluc-P2Y12 (0.36 $\mu$ g of plasmid per dish) in the presence of increasing amounts of PAR4-YFP in ratios 1:1 to 20:1 (0.36 $\mu$ g - 7.2 $\mu$ g of PAR4-YFP). The direct interaction between P2Y12 and PAR4 was assessed using BRET. Briefly, BRET is a measurement of the energy transfer from the donor enzyme (Rluc) which oxidizes its substrate: coelenterazine to coelenteramide, which in turn results in a non-radiative emission at 485nm. When EYFP, the acceptor fluorophore is within 10 nanometers of the Rluc, emission from the coelenteramide at 485 nm in turn excites the EYFP on the neighboring acceptor molecule (Gandia et al., 2008) and results in emission at a peak of 527 nm. The interaction between Rluc-P2Y12 and PAR4-YFP is specific and saturable, as no BRET was detected due to co-expression of Rluc-P2Y12 with either vector expressing YFP alone (Fig. 1B) or with the prostaglandin D2 receptor 1(DP1)-YFP (Fig. 1A). For each BRET assay, a duplicate black 96-well optiplate was used to measure the YFP emission at 535nm in the absence of coelenterazine to assess fold over basal (FOB) YFP expression for 1:1 to 24:1 YFP:Rluc ratios of

transfection. Milli BRET Units (mBU) were plotted as a function of YFP FOB to see saturable interaction between PAR4 and P2Y12 (representative graph shown in supplemental Figure 1). % maximal BRET was calculated as a percent of the maximal mBU achieved per assay and plotted against YFP:Rluc ratio of amount of co-transfected plasmid. Saturation plots showed no difference in the binding curve irrespective of whether YFP:Rluc ratio or FOB axes were used (data not shown) hence % maximal BRET was plotted against YFP:Rluc ratio for all BRET assays. Interaction appears to require activation of both PAR4 and P2Y12, since percent maximal BRET was reduced by 62.5% when P2Y12 was inhibited by P2Y12 antagonist (MeSAMP) (100 $\mu$ M) (Fig. 1A) and increased by 40% in the presence PAR4 agonist (AYPGKF) (200  $\mu$ M) (Fig. 1B). Basal interaction of PAR4 with P2Y12 is probably due to their constitutive activity, since increased constitutive activity of diverse GPCRs has been demonstrated by measuring secondary messenger activities following expression in heterologous systems (Daeffler and Landry, 2000; Milligan et al., 1995; Tiberi and Caron, 1994). A significant increase in net BRET signal following PAR4 activation and decrease in the presence of P2Y12 antagonist suggests that association of PAR4 with P2Y12 is driven by the active states of both receptors.

#### P2Y12 directly associates with PAR4, but not PAR1

To determine whether the agonist-dependent association of P2Y12 with PAR4 is specific, we compared the interaction of P2Y12 with PAR4 and its ability to associate with PAR1. Comparative saturation BRET assays demonstrate that the BRET<sub>50</sub> for PAR4-P2Y12 interaction is  $3.1 \pm 0.4$ ; however, PAR1-YFP did not demonstrate any



detectable saturable BRET with Rluc-P2Y12 and did not differ significantly from BRET with YFP vector control, indicating that PAR1 and P2Y12 do not interact using this system (Fig 2A). To confirm the relative affinity of PAR4 vs. PAR1 for interaction with P2Y12, we compared the ability of untagged PAR4 or PAR1 to compete with the BRET interaction of PAR4-YFP and Rluc-P2Y12. Untagged PAR4 reduced BRET between PAR4-YFP and Rluc-P2Y12 in a dose-dependent fashion to a maximal reduction of 61%; however, untagged PAR1 was unable to compete with the PAR4-P2Y12 interaction at even the highest expression level tested (Fig 2B). These results suggest that PAR1 is unable to directly interact with P2Y12, at least not with an affinity that can compete for the interaction of PAR4 with P2Y12.

#### Residues at the base of PAR4 transmembrane helix 4 are required to promote interaction with P2Y12, but not with itself

Since PAR4 associates specifically with P2Y12, but PAR1 does not (Fig. 2A), we sought to determine residues in PAR4 that are required for the specificity of its interaction with P2Y12 relative to PAR1. Accordingly, we examined the sequence of PAR4 and PAR1 in their transmembrane domains, a common site of GPCR heterodimerization, to determine whether there are specific sites of amino acid sequence divergence between the two receptors. We identified 3 amino acids at the base of the fourth transmembrane domain (TM4) of PAR4 (LGL194-196) that differ significantly from the SFT (220-222) expressed at the aligned sequence of TM4 in PAR1. Based upon the sequence comparison, we designed a variant of PAR4, termed PAR4SFT, that is mutated at these 3 residues (LGL194-196) to contain the corresponding PAR1

residues at the aligned position (SFT 220-222). We found that PAR4SFT fails to interact with P2Y12 when assessed by saturation BRET (Fig. 3A). Notably, residues in the 4<sup>th</sup> transmembrane domain have also been demonstrated to promote PAR4 homodimer formation (de la Fuente et al., 2012). To determine whether residues LGL(194-196) at the base of TM4 also contribute to PAR4 homodimerization, we tested whether PAR4SFT could homodimerize with (wildtype) PAR4 when the two receptors were co-expressed in HEK293T cells and assessed using saturation BRET (Fig 3B). The results show that luciferase-tagged PAR4 interacted equally well with PAR4SFT-YFP as with PAR4-YFP, indicating that these residues specifically support association with P2Y12, but are not required for the homodimeric interaction.

When expressed in HEK293T cells, co-immunoprecipitation of PAR4 or PAR4SFT with P2Y12 also supports this finding (Fig 3A), with an observed increase in PAR4-P2Y12 receptor co-immunoprecipitation upon agonist treatment and a comparatively less co-immunoprecipitation of P2Y12 with PAR4SFT relative to PAR4 (Fig. 4A). All the receptors P2Y12, PAR4 and PAR4SFT were expressed on the HEK293T cell membranes; hence the reduction in co-immunoprecipitation of PAR4SFT and P2Y12 was not due to abnormal receptor trafficking to the membrane (Fig. 4B, C). To determine if endogenous ADP levels in the media could promote the basal PAR4-P2Y12 association observed, co-immunoprecipitation studies were conducted in the presence and absence of apyrase. Figure 4D shows that, apyrase treatment does not alter the basal level of PAR4 and P2Y12 association.

Association of PAR4 with P2Y12 is required for PAR4-dependent recruitment of arrestin-2 and Akt activation

We have previously reported that stimulation of mouse platelets with thrombin or PAR4-AP causes arrestin-2 recruitment to PAR4 in a P2Y12- dependent manner and that PAR4-mediated Akt activation is partially governed by arrestin signaling (Li et al., 2011). To determine whether association of P2Y12 with PAR4 governs the recruitment of arrestin to PAR4 and thus influences the maximal Akt activation observed in response to PAR4 activation, we compared PAR4-dependent arrestin recruitment and Akt activation in cells co-expressing PAR4 with P2Y12 or co-expressing PAR4SFT with P2Y12. HEK293T cells were selected to stably express either HA-tagged PAR4 or HA-tagged PAR4SFT alone or together with Flag-tagged P2Y12. PAR4- or PAR4SFT expressing HEK293T cells were then stimulated with AYPGKF in the presence or absence of the P2Y12 antagonist, MeSAMP. Lysates of PAR4-stimulated cells were immunoprecipitated (IP) with antibody to arrestin-2 and immunoblotted for PAR4 (Fig. 5). We observed that PAR4 co-immunoprecipitates with arrestin-2 upon activation, and only in presence of P2Y12 expression (Fig. 5A, C). When PAR4SFT was co-expressed with P2Y12, it failed to associate with arrestin even after PAR4 activation (Fig. 5B). However P2Y12 can associate with arrestin by itself upon ADP stimulation (Fig 5D) suggesting that PAR4-P2Y12 dimerization assists arrestin recruitment to PAR4 with P2Y12 as a mediator.

Using the previously-described stable cell lines, we next tested whether PAR4-P2Y12 interaction was required for Akt activation. Stimulation with PAR4-AP peptide resulted in substantial Akt activation in PAR4 and P2Y12 co-expressing 293T cells; however,

PAR4-AP failed to cause Akt activation in cells co-expressing PAR4SFT and P2Y12, implying that the failure to dimerize with P2Y12 abolishes the ability of PAR4 to associate with arrestin and influences downstream Akt activation (Fig. 6). When expressed alone, P2Y12 however can activate Akt upon ADP stimulation (Fig 6C).

PAR4SFT fails to induce calcium mobilization independently but potentiates PAR4 mediated calcium flux:

Finally, Gq-coupled calcium mobilization responses of PAR4 and PAR4SFT were assessed by evaluating the relative fluorescence of PAR4-stimulated, Fluo4-AM-loaded HEK293T cells transiently expressing PAR4 or PAR4SFT. When expressed individually, PAR4SFT failed to induce a calcium flux upon stimulation with increasing AYPGKF concentration (from 1-8mM) even though PAR4 and PAR4SFT were expressed with equal efficiency (Fig. 7A, B), implying that it is unable to activate Gq by itself. PAR4 homodimerization has been reported to be essential for calcium mobilization (de la Fuente et al., 2012), hence we reasoned that the defect in calcium mobilization seen with PAR4SFT could be due to the inability of the mutant to form homodimers. Importantly, however, we have shown that PAR4SFT can dimerize with wild type PAR4 (Fig. 3B). Therefore, we hypothesized that dimeric PAR4 is required for functional Gq coupling. Hence we tested whether increased expression of PAR4SFT with (wildtype) PAR4 might alter the minimal amount of PAR4 required to generate a calcium response. When minimal amounts of PAR4 (0.1µg) (enough to see minimal detectable calcium flux) was co-transfected with increasing amounts of PAR4SFT (PAR4:PAR4SFT 1:1 and 1:2), a PAR4SFT receptor dose-dependent increase in

calcium response was detected (Fig. 7C, D), suggesting that PAR4SFT can dimerize with PAR4 to generate a functional dimer. This, together with our BRET data (Fig. 3B) shows that PAR4SFT can dimerize with PAR4, but not with itself to induce Gq-mediated responses.

#### PAR4 induced calcium mobilization influences PAR4 P2Y12 dimerization:

Given that PAR4SFT fails to elicit normal calcium responses when expressed in isolation, we reasoned that the inability of PAR4SFT to dimerize with P2Y12 could be secondary to its defect in eliciting Gq-coupled calcium responses. Hence, we evaluated whether calcium mobilization is required for association of PAR4 with P2Y12 in human platelets and HEK293T cells. Washed human platelets or HEK293T cells co-expressing PAR4 and P2Y12, were treated with calcium chelator, BAPTA-AM 10 $\mu$ M, and then stimulated with AYPGKF 150 $\mu$ M, followed by co-immunoprecipitation of PAR4 and P2Y12. Figure 8A and supplemental figure 2 show that in human platelets and HEK293T cells respectively, PAR4 stimulation promotes PAR4-P2Y12 association and can be blocked by BAPTA-AM. Thus, calcium mobilization is important in promoting receptor-receptor interaction, suggesting at least one mechanism by which receptor activation is required for PAR4-P2Y12 association. Consistent with our previous report, we also demonstrate in human platelets that PAR4-stimulated PAR4-P2Y12 association is prevented by inhibition of P2Y12 (Fig. 8B).

## Discussion

An increasing number of studies have shown that GPCRs can exist as homo- or heterodimers, or higher order oligomers (Milligan, 2008; Milligan et al., 2004; Minneman, 2007; Smith and Milligan, 2010). While the structural determinants governing these interactions and their functional relevance are defined for some receptor pairs (de la Fuente et al., 2012; Frey et al., 2013; Ibrahim et al., 2013; Lagane et al., 2008; Wang et al., 2005), new receptor homo/hetero dimerizations continue to be identified in diverse cells. Some receptor pairs have been shown to support differential signaling responses from those attributed to either receptor alone (Rozenfeld and Devi, 2010; Rozenfeld and Devi, 2011). We report here for the first time that PAR4 and P2Y12, two GPCRs expressed in platelets, undergo activation-dependent direct interaction when expressed in HEK293T cells. We identify a 3 amino acid site in TM4 of PAR4 that, when replaced with aligned residues from its PAR1 counterpart, disrupts the interaction of PAR4 with P2Y12, but not its ability to homodimerize with wildtype PAR4. Further, this mutation also disrupts its ability to recruit arrestin-2 to the PAR4-P2Y12 complex, with commensurate disruption of Akt phosphorylation. Interestingly, expression of PAR4SFT alone fails to support Gq-coupled calcium responses, but potentiates PAR4-mediated calcium responses, suggesting that PAR4 homodimer formation is required for Gq coupling. This study suggests a mechanism by which PAR4 and P2Y12 synergistically may contribute to platelet activation, due to the activation-dependent formation of PAR4-P2Y12 heterodimers, which permits recruitment of arrestin-2 to initiate a unique signaling cascade that can mediate the PI3K-dependent Akt activation (Li et al 2010) to influence platelet activation.

In this study, we demonstrate using saturation BRET in HEK293T cells that the thrombin receptor PAR4 interacts directly with P2Y12 upon agonist activation. Although some interaction is detected in the absence of agonist, this is likely caused by overexpression in the heterologous expression system which can elicit increased constitutive activity (Daeffler and Landry, 2000). An increased net BRET output after PAR4 stimulation and a reduction in BRET in the presence of P2Y12 antagonist (Fig. 1) suggests that exposure of platelets *in vivo* to the physiological release of thrombin during thrombus formation could promote PAR4-P2Y12 heterodimerization and that P2Y12 or PAR4 inhibitors would block this event. Many GPCRs expressed in platelets have been reported to form homo-dimers or -oligomers independent of ligand activation, including PAR4, TP receptor, and P2Y12. Agonist-dependent regulation of PAR4-P2Y12 association in platelets suggests that these heterophilic associations might occur in a regulated, reversible fashion to promote sustained signaling events supporting longer-term thrombus stability.

Association of P2Y12 with PAR4 is specific, since P2Y12 does not interact with PAR1 when assessed by saturation or competition BRET (Fig. 2). Structural motifs governing GPCR interaction have been mapped to the TMs in many receptors (Complement factor A receptor, Chemokine receptors, Dopamine and Beta adrenergic receptors) (Floyd et al., 2003; Klco et al., 2003). Using the sequence divergence of PAR1 from PAR4 in the TM helices as a basis for site-directed mutagenesis, we identified a site at the base of the 4<sup>th</sup> TM helix of PAR4 that disrupts the association between PAR4 and P2Y12, as well as Gq-coupled calcium mobilization. The impairment in PAR4-P2Y12 association could be a consequence of the defect in Gq signaling, implying that PAR4-dependent

calcium mobilization is required to promote PAR4 and P2Y12 dimerization. This further supports the idea that PAR4 activation is necessary for PAR4-P2Y12 dimerization. Interestingly, the leucine zipper of PAR4 TM4 has been reported to be required for PAR4 homodimerization and intracellular calcium mobilization (de la Fuente et al., 2012). Of note, the association of PAR4SFT with wildtype PAR4 is maintained in spite of the mutation (Fig. 3B). This region is near the cytoplasmic interface, but C-terminal to the residues that have previously been shown to be required for PAR4 homodimerization, suggesting that discrete regions of TM4 govern association of PAR4 with another PAR4 protomer versus with P2Y12.

Given the reported existence of constitutive PAR4-PAR1 heterodimers (Leger et al., 2006) in platelets, the inability of PAR1 to compete with the interaction of PAR4 and P2Y12 raises at least two possible interpretations: 1) PAR4 interacts with P2Y12 at a site different from its interaction with PAR1. This possibility is likely, given that the two discrete mutations in TM4 show differential effect on the interaction of PAR4 with itself versus P2Y12 or 2) the affinity of PAR4 for P2Y12 in this HEK293T system is greater than that of PAR4 for PAR1. This may be the case in platelets only when PAR4 and P2Y12 are agonist-activated, since the PAR1-PAR4 interaction is constitutive in platelets, but the PAR4-P2Y12 is not. Although each of these complexes has been detected in platelets by co-immunoprecipitation, the relative amounts of PAR4 in each of these GPCR complexes remains to be quantified, as does whether these different complexes of PAR4 exist in different membrane domains, such as lipid rafts.

Given that receptor activation drives PAR4-P2Y12 association, and these receptors have been shown to play a role in thrombus stability in vivo, we wondered whether



PAR4-P2Y12 association could drive unique signaling events. Multiple studies have observed that signaling consequences of GPCR heterodimers can be different from those detected due to expression of either receptor alone; for example, heterodimers of  $\delta$ - $\kappa$  opioid receptors,  $\delta$ - $\mu$  opioid receptors and  $\alpha$ 2a- and  $\alpha$ 2c adrenergic receptors yield arrestin-dependent signaling responses as heterodimers that are not detected upon expression of the monomers alone (Rozenfeld and Devi, 2007; Rozenfeld and Devi, 2010; Small et al., 2006). Arrestins serve as scaffolding molecules to signal through complexes that include clathrin, adaptin, mdm2, and, of particular relevance to our study, src family kinases (SFK), and PI3K (Gurevich and Gurevich, 2003; Lodeiro et al., 2009; Yang et al., 2009). We previously demonstrated that in mouse and human platelets, PAR4-AP induces a signaling complex of arrestin-2, the p85 subunit of PI3K and the SFK, Lyn, which contributes to Akt activation in a P2Y12 dependent manner (Li et al., 2011). Here, we show that PAR4 supports arrestin recruitment and arrestin-dependent Akt phosphorylation only in the presence of P2Y12 in HEK293T cells (Fig. 5 and 6). In contrast, when PAR4SFT and P2Y12 are co-expressed, arrestin recruitment to AYPGKF-activated PAR4SFT is abolished, and Akt phosphorylation is inhibited. Although many studies have reported that PAR4 signaling to Akt is P2Y12-dependent (Kim et al., 2006; Li et al., 2008), a recent study demonstrated that PAR4 can independently activate Akt in P2Y12 knock-out mice and in COS-7 cells at high agonist concentration (AYPGKF 500 $\mu$ M-1000 $\mu$ M (Xiang et al., 2010). In the current study, co-expression of P2Y12 and PAR4 was required to detect PAR4-dependent Akt phosphorylation. Also our previous study demonstrated that arrestin-2 deletion reduced but did not ablate PAR4-dependent Akt phosphorylation. Taken together, these studies

support a model whereby arrestin scaffolding of PI3K complexes permits the potentiation of Akt phosphorylation by low concentrations of PAR4-AP (150-200 $\mu$ M). Additionally P2Y<sub>12</sub> has been reported to bind arrestin-2 and undergo rapid internalization, suggesting a model whereby the direct interaction of P2Y<sub>12</sub> with arrestin allows PAR4 to recruit arrestin together with P2Y<sub>12</sub> upon PAR4-AP activation (Mundell et al., 2006).

Curiously, mutation of TM4 LGL to residues SFT also disrupted PAR4-dependent calcium responses. This was a surprise, considering that PAR1, like PAR4, also couples to G<sub>q</sub>. Nevertheless, it raises the question of whether this site is required both for PAR4-P2Y<sub>12</sub> interaction and G protein association independently, or whether mutation of PAR4 affects G protein interaction which in turn influences PAR4-P2Y<sub>12</sub> interaction. Interestingly, expressing increasing concentrations of PAR4SFT with co-expressed PAR4 potentiated calcium responses compared to expression of PAR4 alone. This implies that one protomer of PAR4 containing an intact TM4 is sufficient to interact with a PAR4SFT protomer. It also is consistent with a model in which PAR4 exists in a stoichiometric ratio of 2 GPCRs: 1 G protein, which has been the model suggested by previous reports of rhodopsin and leukotriene receptors (Jastrzebska et al., 2013; Liang et al., 2003; Maurice et al., 2011).

In summary, we have shown that agonist-activated PAR4 recruits P2Y<sub>12</sub>-associated arrestin to PAR4 through direct association with P2Y<sub>12</sub>. We have previously shown that arrestin-dependent pathways contribute to Akt activation in platelets which in turn is important for the growth and stability of platelet-rich thrombi in vivo (Li et al., 2011; Woulfe, 2010). Taken together, these studies suggest that the agonist-regulated

association of PAR4 with P2Y12 has functional consequences in promoting the stability of platelet thrombi. While GPCR heterodimerization has been demonstrated in a variety of cell systems, including platelets, their functional relevance in platelets is just beginning to be elucidated. This is the first demonstration of an agonist-regulated formation of a GPCR heterodimer of receptors expressed in platelets that results in a specific signaling consequence. Since we have previously shown that arrestin contributes to Akt activation, which in turn stabilizes platelet thrombi, we propose that agonist-regulated PAR4-P2Y12 association is one mechanism by which PAR4 and P2Y12 synergize to stabilize platelet-rich thrombi. We will test this hypothesis in future studies.

#### Acknowledgements:

We thank Dr. Marvin Nieman (Case Western Reserve University, Cleveland, OH) and Dr. Ji-Fang Zhang, (Thomas Jefferson University, Philadelphia, PA) for providing PAR4 and vector constructs, respectively. Flow Cytometry was performed on AccuriC6 for calcium mobilization assays at the Nemours Cell Science Core. We are grateful to Dr. Sonali Barwe and Sona Lakshme Balasubramanium (A. I. Dupont Children's hospital, Centre for Childhood Cancer research, Wilmington, DE) for assistance with calcium mobilization assays.

Authorship contributions

Participated in research design: Khan, Li, Ibrahim, Smyth, Woulfe

Conducted experiments: Khan, Li, Ibrahim.

Contributed new reagents or analytic tools: Ibrahim, Smyth

Performed data analysis: Khan, Li, Ibrahim, Woulfe.

Wrote or contributed to the writing of the manuscript: Khan, Woulfe.

## References

- Angers S, Salahpour A and Bouvier M (2002) Dimerization: An emerging concept for G protein-coupled receptor ontogeny and function. *Annual Review of Pharmacology and Toxicology* **42**: 409-435.
- Covic L, Gresser AL and Kuliopulos A (2000) Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. *Biochemistry* **39**(18): 5458-5467.
- Daeffler L and Landry Y (2000) Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential. *Fundamental & Clinical Pharmacology* **14**(2).
- de la Fuente M, Noble DN, Verma S and Nieman MT (2012) Mapping Human Protease-activated Receptor 4 (PAR4) Homodimer Interface to Transmembrane Helix 4. *Journal of Biological Chemistry* **287**(13): 10414-10423.
- Filizola M and Weinstein H (2005) The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics. *Febs Journal* **272**(12): 2926-2938.
- Floyd DH, Geva A, Bruinsma SP, Overton MC, Blumer KJ and Baranski TJ (2003) C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast. *J Biol Chem* **278**(37): 35354-35361.
- Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA and Chintala MS (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. *Journal of Clinical Investigation* **107**(12): 1591-1598.
- Frey AJ, Ibrahim S, Gleim S, Hwa J and Smyth EM (2013) Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif. *Journal of Lipid Research* **54**(6): 1678-1690.
- Gandia J, Lluís C, Ferre S, Franco R and Ciruela F (2008) Light resonance energy transfer-based methods in the study of G protein-coupled receptor oligomerization. *Bioessays* **30**(1): 82-89.
- Gurevich VV and Gurevich EV (2003) The new face of active receptor bound arrestin attracts new partners. *Structure* **11**(9): 1037-1042.

Holinstat M, Voss B, Bilodeau ML, McLaughlin JN, Cleator J and Hamm HE (2006) PAR4, but not PAR1, signals human platelet aggregation via Ca<sup>2+</sup> mobilization and synergistic P2Y<sub>12</sub> receptor activation. *J Biol Chem* **281**(36): 26665-26674.

Hoxie JA, Ahuja M, Belmonte E, Pizarro S, Parton R and Brass LF (1993) INTERNALIZATION AND RECYCLING OF ACTIVATED THROMBIN RECEPTORS. *Journal of Biological Chemistry* **268**(18): 13756-13763.

Ibrahim S, McCartney A, Markosyan N and Smyth EM (2013) Heterodimerization With the Prostacyclin Receptor Triggers Thromboxane Receptor Relocation to Lipid Rafts. *Arteriosclerosis Thrombosis and Vascular Biology* **33**(1): 60-+.

Jastrzebska B, Orban T, Golczak M, Engel A and Palczewski K (2013) Asymmetry of the rhodopsin dimer in complex with transducin. *Faseb Journal* **27**(4): 1572-1584.

Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H and Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. *Journal of Clinical Investigation* **103**(6): 879-887.

Kim S, Jin JG and Kunapuli SP (2006) Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. *Blood* **107**(3): 947-954.

Klco JM, Lassere TB and Baranski TJ (2003) C5a receptor oligomerization. I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor. *J Biol Chem* **278**(37): 35345-35353.

Lagane B, Chow KYC, Balabanian K, Levoye A, Harriague J, Planchenault T, Baleux F, Gunera-Saad N, Arenzana-Seisdedos F and Bachelier F (2008) CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. *Blood* **112**(1): 34-44.

Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L and Kuliopulos A (2006) Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. *Circulation* **113**(9): 1244-1254.

Li D, August S and Woulfe DS (2008) GSK3beta is a negative regulator of platelet function and thrombosis. *Blood* **111**(7): 3522-3530.

Li DJ, D'Angelo L, Chavez M and Woulfe DS (2011) Arrestin-2 Differentially Regulates PAR4 and ADP Receptor Signaling in Platelets. *Journal of Biological Chemistry* **286**(5): 3805-3814.

Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K and Engel A (2003) Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. *J Biol Chem* **278**(24): 21655-21662.

- Lin HL and Trejo J (2013) Transactivation of the PAR1-PAR2 Heterodimer by Thrombin Elicits beta-Arrestin-mediated Endosomal Signaling. *Journal of Biological Chemistry* **288**(16): 11203-11215.
- Lodeiro M, Theodoropoulou M, Pardo M, Casanueva FF and Camiña JP (2009) c-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and -dependent mechanisms. *PLoS One* **4**(3): e4686.
- Maurice P, Kamal M and Jockers R (2011) Asymmetry of GPCR oligomers supports their functional relevance. *Trends in Pharmacological Sciences* **32**(9): 514-520.
- Milligan G (2008) A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. *British Journal of Pharmacology* **153**: S216-S229.
- Milligan G, Bond RA and Lee M (1995) INVERSE AGONISM - PHARMACOLOGICAL CURIOSITY OR POTENTIAL THERAPEUTIC STRATEGY. *Trends in Pharmacological Sciences* **16**(1).
- Milligan G, Pediani J, Fidock M and Lopez-Gimenez JF (2004) Dimerization of alpha(1)-adrenoceptors. *Biochemical Society Transactions* **32**: 847-850.
- Minneman KP (2007) Heterodimerization and surface localization of G protein coupled receptors. *Biochemical Pharmacology* **73**(8): 1043-1050.
- Mundell SJ, Luo J, Benovic JL, Conley PB and Poole AW (2006) Distinct clathrin-coated pits sort different G protein-coupled receptor cargo. *Traffic* **7**(10): 1420-1431.
- Niitsu Y, Jakubowski JA, Sugidachi A and Asai F (2005) Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y(12) receptor antagonist activity. *Seminars in Thrombosis and Hemostasis* **31**(2): 184-194.
- Novi F, Stanasila L, Giorgi F, Corsini GU, Cotecchia S and Maggio R (2005) Paired activation of two components within muscarinic M3 receptor dimers is required for recruitment of beta-arrestin-1 to the plasma membrane. *J Biol Chem* **280**(20): 19768-19776.
- Rozenfeld R and Devi LA (2007) Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. *FASEB J* **21**(10): 2455-2465.
- Rozenfeld R and Devi LA (2010) Receptor heteromerization and drug discovery. *Trends Pharmacol Sci* **31**(3): 124-130.
- Rozenfeld R and Devi LA (2011) Exploring a role for heteromerization in GPCR signalling specificity. *Biochemical Journal* **433**: 11-18.



Savi P, Zacharyus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P and Herbert JM (2006) The active metabolite of Clopidogrel disrupts P2Y<sub>12</sub> receptor oligomers and partitions them out of lipid rafts. *Proceedings of the National Academy of Sciences of the United States of America* **103**(29): 11069-11074.

Shapiro MJ, Weiss EJ, Faruqi TR and Coughlin SR (2000) Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. *Journal of Biological Chemistry* **275**(33): 25216-25221.

Small KM, Schwarb MR, Glinka C, Theiss CT, Brown KM, Seman CA and Liggett SB (2006) Alpha<sub>2A</sub>- and alpha<sub>2C</sub>-adrenergic receptors form homo- and heterodimers: the heterodimeric state impairs agonist-promoted GRK phosphorylation and beta-arrestin recruitment. *Biochemistry* **45**(15): 4760-4767.

Smith NJ and Milligan G (2010) Allosterity at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes. *Pharmacological Reviews* **62**(4): 701-725.

Tadokoro S, Nakazawa T, Kamae T, Kiyomizu K, Kashiwagi H, Honda S, Kanakura Y and Tomiyama Y (2011) A potential role for  $\alpha$ -actinin in inside-out  $\alpha$ IIb $\beta$ 3 signaling. *Blood* **117**(1): 250-258.

Tiberi M and Caron MG (1994) HIGH AGONIST-INDEPENDENT ACTIVITY IS A DISTINGUISHING FEATURE OF THE DOPAMINE D<sub>1B</sub> RECEPTOR SUBTYPE. *Journal of Biological Chemistry* **269**(45).

Trejo J and Coughlin SR (1999) The cytoplasmic tails of protease-activated receptor-1 and substance P receptor specify sorting to lysosomes versus recycling. *Journal of Biological Chemistry* **274**(4): 2216-2224.

Wang DX, Sun XC, Bohn LM and Sadee W (2005) Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. *Molecular Pharmacology* **67**(6): 2173-2184.

Woulfe DS (2010) Akt signaling in platelets and thrombosis. *Expert Rev Hematol* **3**(1): 81-91.

Xiang B, Zhang G, Liu J, Morris AJ, Smyth SS, Gartner TK and Li Z (2010) A G(i)-independent mechanism mediating Akt phosphorylation in platelets. *Journal of Thrombosis and Haemostasis* **8**(9): 2032-2041.

Yang M, He RL, Benovic JL and Ye RD (2009) beta-Arrestin1 interacts with the G-protein subunits beta1gamma2 and promotes beta1gamma2-dependent Akt signalling for NF-kappaB activation. *Biochem J* **417**(1): 287-296.

Footnotes:

Parts of this work were funded by an American Heart Association Grant-in-Aid GRNT12040216 and by a pilot project awarded from the National Center for Research Resources [5P30RR031160-03] and the National Institute of General Medical Sciences [P30 GM103519-03] from the National Institutes of Health.

Nemours Cell Science Core is supported in parts by grants from the National Institute of General Medical Sciences [5P20GM103464-09 and 5P20GM103446-13] of the National Institutes of Health.

Reprint requests should be sent to Donna S. Woulfe, 105 The Green, Room # 349, Department of Biological Sciences, University of Delaware, Newark, DE, 19716, USA. Tel.: 302-831-2281, Fax: 302-831-2281; E-mail: [dswoulfe@udel.edu](mailto:dswoulfe@udel.edu)

### Figure Legends:

Figure 1 Saturation BRET of PAR4 and P2Y12 in the presence and absence of PAR4-AP (AYPGKF) and P2Y12 antagonist (MeSAMP): HEK293T cells were transiently co-transfected with 0.36 $\mu$ g of Rluc-P2Y12 and varying amounts (0.36-8.24 $\mu$ g) of PAR4-YFP, DP1-YFP, or YFP-expressing vector control to achieve YFP:Rluc ratios from 1:1-24:1. BRET is expressed in relative % maximal BRET units as described in Methods. (A) P2Y12 antagonist MeSAMP (100 $\mu$ M) treatment for 10 min at RT, reduced the % maximal BRET of Rluc-P2Y12 and PAR4-YFP by  $62.5 \pm 17\%$  ( $p=0.021$ ). The average maximum mBU achieved for RlucP2Y12: PAR4YFP was 50.40 units (N=3) at a ratio of 24:1 which was defined as 100% BRET. Shown is the average  $\pm$  SEM of 3 independent experiments. (B) PAR4 agonist AYPGKF (200 $\mu$ M) treatment for 10min at 37°C increased the % maximal BRET of Rluc-P2Y12 and PAR4-YFP by  $40 \pm 11.06\%$  ( $p=0.019$ ) with an average maximum 475.49mBU (N=4). Shown is the mean  $\pm$  SEM of 4 independent experiments. ( $p= * <0.05$ ,  $** <0.01$ ,  $*** <0.001$ ).

Figure 2 PAR4 and P2Y12 heterodimerize in BRET but PAR1 P2Y12 do not: (A) HEK293T cells were transiently co-transfected with (0.18 $\mu$ g) of Rluc-P2Y12 and varying amounts (0.18-2.88 $\mu$ g) of PAR4-YFP or PAR1-YFP, or YFP-expressing vector control to achieve YFP:Rluc ratios from 1:1-16:1. BRET is expressed in relative % maximal BRET as described in Methods. PAR4YFP:RlucP2Y12 reached an average maximum mBU of 1000 units as compared to only 270mBU for PAR1YFP:RlucP2y12 (N=3). (B) HEK293T cells were transiently co-transfected with Rluc-P2Y12 (0.18 $\mu$ g) and PAR4-YFP (2.16 $\mu$ g) at a saturating ratio of 12:1 (YFP:Rluc) (max mBU= 30.72 units) and increasing

amounts of HA tagged PAR4 (open circles) or PAR1(closed circles) from ratio 4:1 to 24:1 of competitor:Rluc. HA-PAR4 was able to compete off Rluc-P2Y12 and PAR4-YFP dimerization and reduced the % maximal BRET in a dose dependent manner but HA-PAR1 could not. Shown is the mean  $\pm$  SEM of 3 independent experiments. ( $p = * < 0.05$ , \*\*  $< 0.01$ , \*\*\*  $< 0.001$ )

Figure 3 PAR4SFT fails to dimerize with P2Y12 in saturation BRET, but still dimerizes with wild type PAR4: HEK293T cells were transiently co-transfected with (0.18 $\mu$ g) of Rluc-P2Y12 (A) Rluc-PAR4 (B) and varying (amounts) of PAR4-YFP or PAR4SFT-YFP, or YFP-expressing vector control to achieve YFP:Rluc ratios from 1:1-16:1 (0.18 $\mu$ g-2.88 $\mu$ g). BRET is expressed in relative % maximal BRET. (A) PAR4SFT supported only 8.74% of PAR4 P2Y12 dimerization in saturation BRET where PAR4YFP:RlucP2Y12 achieved an average maximum 104.40mBU at a ratio of 16:1. (B) PAR4SFT-YFP homodimerized equally well with Rluc-PAR4, like PAR4-YFP with an average max 268.08mBU for PAR4YFP:RlucPAR4 and 260.24mBU for PAR4SFTYFP:RlucPAR4 at a 16:1 ratio. Shown are the mean  $\pm$  SEM of 3 and 4 independent experiments, respectively. ( $p = * < 0.05$ , \*\*  $< 0.01$ , \*\*\*  $< 0.001$ ).

Figure 4 PAR4 co-immunoprecipitates with P2Y12 upon PAR4-AP stimulation, but PAR4SFT does not in HEK293T cells: (A) HEK293T cells stably expressing Flag-tagged P2Y12 were transiently transfected with V5-PAR4-GFP or HA-PAR4SFT-GFP. 48 hours post transfection cells were left untreated or stimulated with AYPGKF(200 $\mu$ M) 10min at 37°C with and without MeSAMP (150 $\mu$ M) 10min at RT. Cell were lysed, immunoprecipitated with anti-Flag antibody (Abcam 1:1000) and immunoblotted for

antibody to GFP (MBL 1:500). (B, C) Surface expression of P2Y12, PAR4 and PAR4SFT in HEK293T cells: HEK293T cells stably expressing Flag-P2Y12 (B) and transiently expressing HA-PAR4 or HA-PAR4SFT(C), were versinized, washed with 1X PBS and resuspended to be fixed in DMEM+ 5% FBS, stained with anti-Flag and anti-HA and probed with Alexa-488 secondary antibody to test the membrane expression of these receptors, cells were fixed post staining. (D) HEK293T cells transiently expressing V5-PAR4-GFP and Flag-P2Y12 were treated with apyrase (2U/ml) and AYPGKF (200 $\mu$ M), lysed and immunoprecipated with anti Flag (2  $\mu$ g/ml) and immunoblotted with anti V5 (1:1000).

Figure 5 Arrestin co-immunoprecipitates with PAR4 only in the presence of P2Y12 and depends on PAR4 P2Y12 dimerization: HEK293T cells stably expressing HA-PAR4 or HA-PAR4SFT or co-expressing it along with Flag-P2Y12 were left untreated or stimulated with AYPGKF (200 $\mu$ M) 10min at 37°C with and without MeSAMP (150 $\mu$ M) 10min at RT. Cell were lysed, immunoprecipated with antibodies to arrestin-2 (santa Cruz, 2 $\mu$ g/ml) and immunoblotted for PAR4 (1:1000)(Santa Cruz) (5A,B,C) . P2Y12 stable cells were treated as shown and immunoprecipated with anti Flag (2  $\mu$ g/ml) and immunoblotted for Arrestin-2 (1:1000) (santa Cruz) (5D).



Figure 6: Akt phosphorylation in response to PAR4 activation in cells co-expressing PAR4 or PAR4SFT and P2Y12: Stable HEK293T cell lines were stimulated with AYPGKF (200 $\mu$ M) 10min at 37°C with and without MeSAMP (150 $\mu$ M) 10min at RT, lysed, and immunoblotted for phospho Akt using anti-p-Akt473 (cell signaling 1:500).

Pan-actin and total Akt were used as loading controls (1:1000, Cell signaling). Shown is a representative blot (A) and an averaged quantification of normalized phospho Akt levels  $\pm$  SEM for 3 independent experiments. ( $p = * < 0.05$ ). C) P2Y12 stable cells were treated as shown, lysed and immunoblotted for phospho Akt using anti-p-Akt473 (cell signaling 1:500). Pan-actin was used as loading control (1:1000, Cell signaling).

Figure 7: Mutating TM4 residues LGL (194-196) to SFT disrupts the ability of PAR4 to induce calcium mobilization in response to PAR4-AP: HEK293T cells transiently transfected with V5-PAR4-GFP or HA-PAR4SFT-GFP. 48 hours post transfections cells collected and loaded with Fluo4AM for 20min at 37°C. Calcium mobilization was measured as Fluo4AM intensity. Baseline cytosolic calcium levels were recorded for 1min followed by AYPGKF 2mM stimulation on AccuriC6 Flow cytometer. Shown is a representative overlay (A) of the calcium mobilization in response to AYPGKF. (B) Transfection efficiency of PAR4 and PAR4SFT was tested by the GFP signal in unloaded HEK293T cells. (C, D) Co-expression of PAR4SFT with PAR4 potentiates calcium mobilization above minimal detectable PAR4 response to AYPGKF: HEK293T cells were transiently transfected with 0.1 $\mu$ g of PAR4 alone and or co-transfected with PAR4 (0.1 $\mu$ g):PAR4SFT (0.1 $\mu$ g and 0.2 $\mu$ g) at 1:1 and 1:2 ratio. Calcium mobilization was assessed as described in (A). Shown is the % increase in Fluo4AM intensity above threshold  $\pm$ SEM of 4 independent experiments ( $p = ** < 0.01$ ).

Figure 8: Chelating cytosolic calcium post PAR4 activation blocks PAR4 P2Y12 dimerization: Human platelets ( $4 \times 10^8$ /lane) were treated with AYPGKF (150 $\mu$ M) 5 min at 37 °C with/without BAPTA-AM (20 $\mu$ M ) for 10 min at 37 °C (A) or MeSAMP (100 $\mu$ M) 5 min at RT (B), then immunoprecipitated with either IgG control or antibody to PAR4 (2 $\mu$ g/ml). Precipitates were immunoblotted with anti-P2Y12 antibody (1:1000).


# Figure 1






**Figure 2**


**A**



**B**






**Figure 3**



**Figure 4****A**

IP: P2Y12


IB: PAR4

**B****C****D**

IP: P2Y12

IP: PAR4

IP: P2Y12



**Figure 5**


**A) PAR4+P2Y12**

IP: Arrestin-2

IgG      AYPGKF      AYPGKF+MeSAMP      Untreated      Unt+MeSAMP

IB: PAR4

IB: Arrestin-2




**B) PAR4SFT+P2Y12**

IP: Arrestin-2

IgG      AYPGKF      AYPGKF+MeSAMP      Untreated      Unt+MeSAMP

IB: PAR4SFT

IB: Arrestin-2



**C) PAR4**

IP: Arrestin-2

IgG      AYPGKF      AYPGKF+MeSAMP      Untreated      Unt+MeSAMP

IB: PAR4

IB: Arrestin-2




**D) P2Y12**

IP: P2Y12

IgG      untreated      Apyrase      ADP      ADP+Apyrase


IB: Arrestin-2

IB: P2Y12




**Figure 6**


**A**



**B**



**C**








**Figure 7**

Figure 8

A



B

